scholarly journals Long-Term Triple Therapy De-escalation to Indacaterol/Glycopyrronium in Patients with Chronic Obstructive Pulmonary Disease (SUNSET): A Randomized, Double-Blind, Triple-Dummy Clinical Trial

2018 ◽  
Vol 198 (3) ◽  
pp. 329-339 ◽  
Author(s):  
Kenneth R. Chapman ◽  
John R. Hurst ◽  
Stefan-Marian Frent ◽  
Michael Larbig ◽  
Robert Fogel ◽  
...  
Keyword(s):  
Chronic Obstructive Pulmonary Disease ◽  
Clinical Trial ◽  
Triple Therapy ◽  
Pulmonary Disease ◽  
Chronic Obstructive ◽  
Double Blind ◽  
Obstructive Pulmonary Disease

scholarly journals Triple therapy in chronic obstructive pulmonary disease

2019 ◽  
Vol 29 (2) ◽  
pp. 199-206
Author(s):  
Sergey N. Avdeev ◽  
Natal’ya V. Trushenko
Keyword(s):  
Chronic Obstructive Pulmonary Disease ◽  
Triple Therapy ◽  
Pulmonary Disease ◽  
Inhaled Corticosteroids ◽  
Chronic Obstructive ◽  
Published Data ◽  
Triple Combination ◽  
Obstructive Pulmonary Disease ◽  
Consensus Statements

Recently, therapeutic options for treatment of chronic obstructive pulmonary disease (COPD) has been significantly extended, mainly due to new double and triple drug combinations in a single inhaler. Double combinations for treatment of COPD include long-term acting beta-2-agonists (LABA)/long-term acting muscarinic antagonists (LAMA) and LABA/inhaled corticosteroids (ICS); a triple combination is a combination of LABA, LAMA and ICS in a single inhaler. A review of consensus statements, national guidelines and recently published data about use of triple therapy in COPD, efficacy and safety of a triple combination is given in the article.

Sign in / Sign up

Export Citation Format

Share Document